-
Mashup Score: 6
APCCC 2024 ideal sequence after ADT alone or ADT + ARPI for treatment in the metastatic hormone sensitive prostate cancer (mHSPC) setting, NCCN prostate cancer guidelines,
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 8APCCC 2024: When to Do Tumor Genomic Profiling in Advanced Prostate Cancer and What? - 3 hour(s) ago
APCCC 2024 tumor genomic profiling in advanced prostate cancer, prostate cancer biopsies, clonal hematopoiesis of indeterminate potential (CHiP), Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) database.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 15APCCC 2024: Future Changes in the Setting of mHSPC - 17 hour(s) ago
APCCC 2024 management of mHSPC, future changes in the setting of mHSPC, role for immune checkpoint inhibition in unselected M1 prostate cancer among men starting ADT, CAPItello-281, AMPLITUDE, TALAPRO-3, PSMAddition, CYCLONE-03.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 8APCCC 2024: Management of Frail Patients with mHSPC - 19 hour(s) ago
APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), Management of Frail Patients with mHSPC, M1 disease, abiraterone, prednisolone, abiraterone plus prednisolone, androgen deprivation therapy (ADT), enzalutamide, apalutamide, darolutamide, LHRH antagonists, androgen receptor pathway inhibitor (ARPI).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 14APCCC 2024: Management of Patients with mHSPC and Early Progression on Combination Therapy - 20 hour(s) ago
APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), mHSPC and early progression on combination therapy, androgen deprivation therapy (ADT), abiraterone, enzalutamide, apalutamide, darolutamide, androgen deprivation therapy plus abiraterone, androgen deprivation therapy plus enzalutamide, androgen deprivation therapy plus apalutamide, androgen deprivation therapy plus darolutamide, ENZAMET trial, PSMAfore trial, p53, RB1, PTEN, oligometastatic prostate cancer, VISION trial, LuPSMA, cabazitaxel, LuPSMA versus cabazitaxel, PROfound trial, TAX-327 trial, mitoxantrone, olaparib, TROPIC trial, CARD trial.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 15APCCC 2024: Genomic Classifiers and Artificial Intelligence as Predictors for Treatment Benefit - 20 hour(s) ago
APCCC 2024 advanced prostate cancer, use of genomic classifiers and artificial intelligence tools as predictors of treatment benefit in prostate cancer patients, prostate cancer mortality, Decipher®.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 12APCCC 2024: Which Patients with mHSPC Can Be Offered a Treatment Break (De-Escalation Strategies) and How to Manage the Break? - 20 hour(s) ago
APCCC 2024 management of mHSPC, EMA established the Cancer Medicines Forum, androgen deprivation and continuing the ARTA, LIBERTAS study, EMBARK, DE-ESCALATE EORTC 2238 trial, intermittent androgen deprivation.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 9APCCC 2024: Update on the IRONMAN Project - 20 hour(s) ago
APCCC 2024 update on the IRONMAN project, IRONMAN Executive Committee, treatment of advanced prostate cancer, Engaging Men in Patient Reported Outcomes, PROfound study, abiraterone, enzalutamide, apalutamide, darolutamide, Movember Foundation.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 9APCCC 2024: Escalation Strategies in Patients with mHSPC and an Unfavourable PSA Decline – Is More Better? - 21 hour(s) ago
APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), Escalation Strategies in Patients with mHSPC, Unfavourable PSA Decline, PSA progression, radiographic progression, clinical progression, CHAARTED data, LATITUDE trial, Titan Trial, STAMPEDE data.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 13APCCC 2024: In Which Patients with Metachronous Low-volume mHSPC Do You Recommend “total Therapy”? - 21 hour(s) ago
APCCC 2024 metastatic hormone-sensitive prostate cancer (mHSPC), metachronous low-volume mHSPC, ‘total therapy’ with metastasis-directed therapy (MDT), ‘Pokemet’ approach,
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
Ideal sequence after ADT alone or ADT plus ARPI for #mHSPC. Presented by @Prof_IanD @EHCSMonash. #APCCC24 Written coverage by @zklaassen_md @GACancerCenter > https://t.co/bER9HKGhlc @APCCC_Lugano https://t.co/CpW4ZK02Cu